The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma

@article{Shoji2013TheCS,
  title={The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma},
  author={Sunao Shoji and Mayura Nakano and Haruhiro Sato and Xianhua Tang and Yoshiyuki Osamura and Toshiro Terachi and Toyoaki Uchida and Koichi Takeya},
  journal={Clinical \& Experimental Metastasis},
  year={2013},
  volume={31},
  pages={111-134}
}
AbstractAppropriate use of multiple reliable molecular biomarkers in the right context will play a role in tailor-made medicine of clear cell renal cell carcinoma (RCC) patients in the future. A total of 11,056 patients from 53 studies were included in this review. The article numbers of the each evidence levels, using the grading system defined by the Oxford Centre for Evidence-based Medicine, in 1b, 2a, 2b, and 3b were 5 (9 %), 18 (34 %), 29 (55 %), and 1 (2 %), respectively. The main goal of… 
Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer.
TLDR
A large cohesive effort is required to advance the field of clear cell renal cell cancer prognostic biomarkers through systematic discovery, verification, validation and clinical implementation.
Modern approaches to kidney cancer immunotherapy
TLDR
A detailed description of the PD-1 receptor and its PD-L1 ligand, as well as the prognostic and predictive significance of their expression in various types of renal cell carcinoma and the role in suppressing the antitumor T-cell immune response are presented.
Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation
TLDR
A realistic preclinical model of papillary renal cell carcinoma carrying an activating mutation of MET is established and the ability of cabozantinib, an inhibitor of receptor tyrosine kinases including MET, to inhibit tumor growth and metastasis is tested.
Altered Expression of DDR1 in Clear Cell Renal Cell Carcinoma Correlates With miR-199a/b-5p and Patients' Outcome
TLDR
DDR1 expression is altered inccRCC, but the findings do not support its oncogenic role, and in-depth investigation will be necessary to elucidate the exact role and potential utility of miR-199a/b-5p in ccRCC.
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
TLDR
New developments in the field of CSC research are discussed and whether these new concepts can be exploited in clinical practice in the future.
Syddansk Universitet Nuclear localization of the CK 2-subunit correlates with poor prognosis in Clear Cell Renal Cell Carcinoma
TLDR
The results suggest that CK2α promotes migration and invasion of ccRCC and therefore could serve as a novel prognostic biomarker and molecular therapeutic target in this type of cancer.
IKBKB expression in clear cell renal cell carcinoma is associated with tumor grade and patient outcomes.
TLDR
The findings indicate that IKBKB protein may be of clinical relevance in ccRCC, serving as a marker of poor prognosis and as potential target for adjuvant chemotherapies.
University of Southern Denmark Nuclear localization of the CK2α-subunit correlates with poor prognosis in Clear Cell Renal Cell Carcinoma Rabjerg,
TLDR
The results suggest that CK2α promotes migration and invasion of ccRCC and therefore could serve as a novel prognostic biomarker and molecular therapeutic target in this type of cancer.
Kidney cancer and 2014: is innovation really over?
TLDR
The consolidated knowledge regarding the role of surgery in localized and advanced renal cell carcinoma and the targeted therapies already approved for metastatic renal cell cancer are analyzed.
...
...

References

SHOWING 1-10 OF 216 REFERENCES
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
TLDR
Serum CA9 levels may be of clinical interest to predict the outcome for patients under targeted therapy for metastatic clear-cell RCC, and may be used to select patients with metastaticclear cell RCC for clinical trials.
Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma
TLDR
A staging system for clear cell variants of renal cell carcinoma (RCC) that includes molecular predictors and standard clinical predictors such as tumor-node-metastasis (TNM) stage, histological grade, and performance status (PS) is proposed.
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis
TLDR
Routine use of this marker may allow better diagnosis, risk stratification, risk-adjusted follow-up, and identification of patients with a greater likelihood of response to targeted therapy.
Prognostic evaluation of COX-2 expression in renal cell carcinoma.
TLDR
COX-2 protein expression is associated with slow development of metastases, and favourable prognosis in metastatic RCC.
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
TLDR
This panel of proteins may be of value as biomarkers of the pharmacological and clinical activity of sunitinib in RCC, and of angiogenic processes in cancer and other diseases.
Understanding the importance of smart drugs in renal cell carcinoma.
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
TLDR
Results suggest that phospho-S6 and pAkt expression are promising predictive biomarkers for response to temsirolimus that are worthy of further exploration for use in patient selection models for mammalian target of rapamycin inhibitors.
The role of pharmacogenomics in metastatic renal cell carcinoma
TLDR
Single nucleotide polymorphisms (SNPs) associated with outcome and toxicity following targeted therapies and recommendations for future trials to facilitate the use of SNPs in personalized therapy for this disease are provided.
...
...